CA-QAD-INC
14.5.2024 09:01:37 CEST | Business Wire | Press release
QAD Inc., a leading provider of next-generation manufacturing and supply chain solutions in the cloud, has opened registration for its new EMEA customer conference, QAD Transform Europe, a complimentary two-day event happening 24-25 September in Brussels, Belgium.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514413631/en/
Customers, sponsors and other members of the QAD community will join manufacturing and supply chain leaders from across Europe for two days of networking, education and technology innovation. Attendees will hear from industry experts and peers about the state of manufacturing and supply chains, what the future may bring and how to stay adaptive.
“QAD Transform Europe is our fresh take on regional events designed for and tailored to the customer,” said QAD Chief Product and Marketing Officer Carter Lloyds. “We recognize that manufacturing and supply chain leaders continue to face uncertainty and change in their business. The only way to survive and thrive is to transform. We look forward to sharing our roadmap for transformation at the event.”
The agenda for QAD Transform Europe will address the fundamental reasons businesses need to transform to survive, and help map the journey to get there. QAD leaders will outline the company’s plans for how to navigate today and tomorrow and QAD customers will share their success stories.
Agenda Highlights:
- Introducing the Industrial Transformation Platform — QAD’s roadmap to help companies transform into an Adaptive Enterprise by QAD CEO Anton Chilton
- Panel discussion with industry leaders on the transformation imperative
- Effective change management across your organization
- Uncovering root causes — not symptoms — of supply chain disruption
- Keynote address on QAD’s technology strategy and the benefits of the Cloud with QAD CTO Tony Winter
- Keynote address on Artificial Intelligence with Jeroen Baert, Computer Scientist, Comedian, Geek
- Leveraging pragmatic AI in supply chains
- Aligning ESG and sustainability with commercial objectives
- QAD new flagship ERP release — ERP O³
- Product updates on QAD Redzone Connected Workforce, QAD GTTE, QAD SRM, QAD DSCP and QAD Process Intelligence
- The new QAD roadmap for the food and beverage industry
- Breakout sessions and QAD Sponsor Expo
On Day 1, QAD executives and guest speakers will share an update on QAD today and the Industrial Transformation Platform, a panel discussion with industry experts on the need for transformation, the QAD roadmap and customer success stories. A networking reception and dinner with fellow manufacturing and supply chain leaders will follow.
On Day 2, guest keynotes will present on Effective Change Management, followed by a presentation on the state of Artificial Intelligence. More great breakout sessions and a networking lunch with QAD will follow as well as a Sponsor Expo to see QAD solutions in action.
The full agenda can be accessed here. For the latest updates on QAD Transform Europe, follow us on social media and engage using #QADTransform.
Event Details
What: QAD Transform Europe Customer Conference
When: 24-25 September, 2024
Where: Cardo Brussels Hotel | Brussels, Belgium
Registration: To register to attend QAD Transform Europe, click here.
About QAD – Enabling Adaptive Enterprises
QAD Inc. is a leading provider of next-generation manufacturing and supply chain solutions in the cloud. To succeed in a turbulent world, facing disruptions in supply and fluctuations in demand, manufacturers and supply chains must rapidly respond to change and seamlessly optimize agility, efficiency, and resilience for effective customer service. QAD delivers Adaptive Applications to enable these Adaptive Enterprises.
Founded in Santa Barbara, California, QAD has customers in 84 countries around the world. Thousands of companies have deployed QAD enterprise solutions including enterprise resource planning (ERP), digital commerce (DC), supplier relationship management (SRM), digital supply chain planning (DSCP), global trade and transportation execution (GTTE), enterprise quality management system (EQMS), connected workforce and process intelligence. To learn more, visit www.qad.com or call +1 805-566-6100. Find us on LinkedIn, X, Facebook and Instagram.
“QAD” is a registered trademark of QAD. All other products or company names herein may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514413631/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom